title: Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia.
abstract: OBJECTIVE
  The objective of the study was to evaluate the effectiveness of single-dose methotrexate in women with low-risk gestational trophoblastic neoplasia.
  
  
  METHODS
  In this prospective observational cohort study, 105 women with low-risk gestational trophoblastic neoplasia were treated with an intravenous bolus of 100 mg/m2 of methotrexate followed by a 12-hour infusion of 200 mg/m2. If the human chorionic gonadotropin level fell 10-fold after 2 weeks, no further chemotherapy was given. Characteristics between the 2 groups with or without complete remission with this regimen were compared.
  
  
  RESULTS
  The overall complete remission rate with methotrexate was 84.8%, with 44.8% of women requiring a single dose of methotrexate alone. The pretreatment human chorionic gonadotropin level was found to be significantly higher in women who failed the single-dose methotrexate regimen (P = .001), and 10 of 11 patients with metastases required further doses.
  
  
  CONCLUSIONS
  This regimen offers an effective option for women with low-risk gestational trophoblastic neoplasia without metastases and a low pretreatment human chorionic gonadotropin level.
authors.affiliation: Department of Obstetrics and Gynecology, University of Hong Kong, Hong Kong. kklchan@hkucc.hku.hk
authors.forename: Karen K L
authors.initials: KK
authors.lastname: Chan
authors.forename: Yong
authors.initials: Y
authors.lastname: Huang
authors.forename: Kar Fai
authors.initials: KF
authors.lastname: Tam
authors.forename: Ka Yu
authors.initials: KY
authors.lastname: Tse
authors.forename: Hextan Y S
authors.initials: HY
authors.lastname: Ngan
mesh_terms: D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000097:blood; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011247:Pregnancy; D011446:Prospective Studies; D012074:Remission Induction; D019233:Retreatment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D006063:Chorionic Gonadotropin; D008727:Methotrexate